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The purpose of the study was to determine the maximum-tolerated dose (MTD) of oral capecitabine, combined with concurrent,
standard preoperative pelvic radiotherapy, when given twice daily, from Monday to Friday throughout the course of radiotherapy, for
locally advanced potentially resectable rectal cancer. Maximum-tolerated dose was defined as the total (given in two equally divided
doses) oral dose of capecitabine that caused treatment-related grade 3 or 4 toxicity in one-third or more of the patients treated.
Radiotherapy involved 50.4Gy given in 28 fractions in 5 weeks and 3 days. Eligible patients had a newly diagnosed clinical stage T3–4
N0–2 M0 rectal adenocarcinoma located within 12cm of the anal verge suitable for curative resection. Surgery was performed 4–6
weeks from completion of preoperative chemoradiotherapy. In all, 28 patients were enrolled in the study at predefined dose levels:
850mgm
 2day
 1 (n¼3), 1000mgm
 2day
 1 (n¼6), 1250mgm
 2day
 1 (n¼3), 1650mgm
 2day
 1 (n¼3), 1800mgm
 2day
 1
(n¼8) and 2000mgm
 2day
 1 (n¼5). The mean age was 62.3 years (range: 33–80 years). Five patients were female and 23 male.
The median distance of tumour from the anal verge was 6cm (range: 1–11cm). Endorectal ultrasound was performed in 93% of
patients. A total of 26 patients (93%) had T3 disease and two patients had resectable T4 disease. Dose-limiting toxicity (DLT)
developed in one patient at dose level 1000mgm
 2day
 1 (RTOG grade 3 cystitis). Two of the five patients at dose level
2000mgm
 2day
 1 had a total of three DLT (grade 3 perineal skin reaction, grade 3 diarrhoea and grade 3 dehydration). Dose
escalation of capecitabine was ceased at 2000mgm
 2day
 1 after reaching MTD. None of the eight patients at dose level
1800mgm
 2day
 1 developed DLT. All except one patient underwent surgery. A total of 15 patients had the clinical T stage reduced
by at least one stage in pathologic specimens. Five patients (19%) achieved a pathologic complete response. We conclude that the
MTD of capecitabine was reached at a dose level of 2000mgm
 2day
 1, given as 1000mgm
 2 twice daily, from Monday to Friday
throughout the course of preoperative pelvic irradiation of 50.4Gy. For patients with resectable rectal cancer receiving concurrent,
full dose radiotherapy, the recommended dose of capecitabine for further study is 1800mgm
 2day
 1 when given in this schedule.
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Local recurrence after curative treatment remains a very sig-
nificant cause of morbidity from carcinoma of rectum as the pelvic
anatomy limits lateral resection margins (Rich et al, 1983; Chan
et al, 1985; Quirke et al, 1986). Combined postoperative radio-
therapy and chemotherapy reduces the rate of local recurrence and
prolongs survival in patients with Dukes B2 and C rectal cancer
(Thomas and Lindblad, 1988; Krook et al, 1991; O’Connell et al,
1994). As a result, adjuvant chemoradiation has been recom-
mended as standard therapy for Dukes B2 and C rectal cancer
(NIH Consensus Conference, 1990). Although a quality of life
study has confirmed the value of postoperative adjuvant radio-
therapy and chemotherapy, concern about treatment-related
toxicity remains (Ooi et al, 1999).
Preoperative radiotherapy has the potential advantages of less
acute and long-term toxicity (Sauer, 2003). Intra-abdominal
adhesions are uncommon in the undisturbed peritoneal cavity,
in which small bowel is freely mobile. Placing the patient in the
prone treatment position allows the small intestine to move out of
the radiation volume, thereby reducing the risk of radiation
enteritis. In the preoperative setting, the local tissue environment
is also more favourable with the tumour having a better blood
supply, thus minimising the problem of hypoxia – an important
cause of failure of radiotherapy. Another potential advantage is the
increased chance of sphincter preservation in locally advanced
rectal cancer as a result of tumour response (Crane et al, 2003), but
it remains a controversial issue.
Although randomised trials have shown that short-course
hypofractionated radiotherapy reduces local recurrence and
improves survival (Swedish Rectal Cancer Trial, 1997; Camma
et al, 2000; Kapiteijn et al, 2001), this approach has not been
accepted worldwide as the standard preoperative approach.
However, preoperative radiotherapy in conventional fractionation
schedules, given concurrently with continuous infusion 5-fluor-
ouracil (5FU), has been widely adopted as the preferred
preoperative regimen, given the acceptable toxicity profile and
efficacy when this regimen is given in the postoperative setting
(O’Connell et al, 1994).
Received 26 April 2004; revised 30 June 2004; accepted 30 June 2004;
published online 10 August 2004
*Correspondence: Dr S Ngan; E-mail: Sam.Ngan@petermac.org
British Journal of Cancer (2004) 91, 1019–1024
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
lInfusional 5FU requires a central venous access line and an
ambulatory delivery system. It is inconvenient to the patient and
carries risks including venous thrombosis, infection and intrave-
nous line migration. An effective oral delivery 5FU would
overcome these problems.
Capecitabine is an oral fluoropyrimidine. Its efficacy as first-line
treatment in metastatic colorectal cancers (MCRC) has been shown
in randomised trials (Twelves, 2002). Its safety as an alternative to
intravenous 5FU-based adjuvant therapy for colon cancer has been
addressed (Scheithauer et al, 2003). Capecitabine achieves long-
term inhibition of the target enzyme thymidylate synthase, and in
this way mimics the continuous intravenous infusion of 5FU. It has
the additional important theoretical advantage of the targeted
production of 5FU in malignant cells via the enzyme thymidine
phosphorylase (TP), which is overexpressed in tumour vs normal
tissue (Miwa et al, 1998). In addition, radiotherapy is known to
further upregulate TP, and in xenograft models, capecitabine and
radiation have shown supra-additive activity (Sawada et al, 1999).
Therefore, the combination of capecitabine with radiotherapy
merits clinical investigation. Thus, a phase I trial of the
combination of standard, preoperative radiotherapy and escalating
doses of concurrent capecitabine was undertaken to assess the
risk/benefit ratio.
PATIENTS AND METHODS
The protocol, detailed patient information sheet and consent form
were reviewed and approved by the human research ethics
committees of participating centres. The trial was conducted in
accordance with the Declaration of Helsinki, International Good
Clinical Practice principles as described in the International
Conference of Harmonisation (ICH) guidelines for Good Clinical
Practice, as well as in accordance with all local ethical and
regulatory requirements. Signed informed consent of patients was
obtained before any trial-specific procedures were performed.
Eligibility criteria
For this trial, eligible patients were required to have a
pathologically documented adenocarcinoma of the rectum with
the lower limit within 12cm from the anal verge. Patients were 18–
75 years old, although patients over the age of 75 years were
eligible if in the opinion of the investigators they were fit and well
for the purposes of the trial. Patients had to be considered suitable
for curative resection by the participating surgeon at the time of
study entry. Tumours were clinical stage T3–T4 tethered, or with
radiological (ultrasound or CT) evidence of perirectal fat infiltra-
tion or nodal involvement. Examples of resectable T4 lesions were
a rectovaginal or rectovesical fistula. The patient had to have a
World Health Organisation (WHO) performance status of 0, 1 or 2.
Patients with recurrent rectal cancer were not eligible.
The exclusion criteria were previous pelvic or abdominal
radiotherapy or a scheduled dose of less than 50Gy or treatment
with high-dose per fraction (42Gy). Patients with evidence of
metastatic disease, history of seizures, central nervous system
disorders, clinically significant psychiatric disability, dementia,
altered mental status or psychosis were not eligible. Patients with a
history of severe and unexpected reaction to fluoropyrimidine
therapy possibly related to DPD deficiency, or known hypersensi-
tivity to 5FU were excluded. Patients with abnormal haematologic
values (absolute neutrophil count o1.5 10
9l
 1, platelet count
o100 10
9l
 1,H bo9gdl
 1) or moderate to severe renal
impairment, that is, creatinine clearance p50mlmin
 1,a s
calculated by the Crockroft Gault formula were not eligible. The
use of blood transfusions to render patients eligible was allowed,
but the use of growth factors to aid haematologic recovery was not
allowed within 2 weeks before the start of or during the course of
treatment. Pregnant or lactating women, women of child-bearing
potential with either a positive pregnancy test at baseline or not
using a reliable and appropriate contraceptive method were not
eligible. Other exclusion criteria were autologous or allogeneic
organ grafts, lack of physical integrity of the upper gastrointestinal
tract, malabsorption syndromes, inability to tolerate or absorb oral
medication or positive hepatitis B surface antigen, hepatitis C
antibodies or human immunodeficiency virus type 1 or 2
antibodies.
Trial design
This was a phase I trial of escalating doses of capecitabine
combined with concurrent preoperative conventionally fractio-
nated radiotherapy for locally advanced, potentially resectable
rectal cancer. The primary objective was to determine the
maximum-tolerated dose (MTD) of intermittent, twice daily oral
capecitabine given with pelvic radiotherapy (in the schedule
described) through the assessment of both subjective and objective
adverse events reported during and up to 6 weeks after treatment.
The secondary objectives were to determine the safety profile of
the combination regimen and to describe any evidence of
antitumour activity. The MTD was defined as the total oral dose
(given in approximately two equally divided daily doses) of
capecitabine when given intermittently (Monday to Friday) from
the first till the last day of standard technique pelvic radiotherapy,
which caused drug-related grade 3/4 toxicity in one-third or more
of the patients treated (i.e. two or more in a six patient cohort).
Three patients were entered at each dose level. Subsequent dose
levels were not opened until all three patients (or all additional
patients where toxicity required more patients to be treated) had
reached the 2-week point beyond the completion of concurrent
chemotherapy and radiotherapy. If none of the three patients
experienced a dose-limiting toxicity (DLT), then recruitment
began at the next dose level. Otherwise, (a) when a DLT was seen
in one patient out of the three patients, three additional patients
were recruited on this dose level. If a DLT was observed in only
one of the six patients, then recruitment began at the next dose
level. If DLTs were observed in two or more of the six patients, no
further dose escalation was to take place. (b) If two or more
patients of the first three patients on a dose level had DLTs, no
further dose escalation was to take place. The MTD was defined at
that dose level. DLT was defined as grade 3 or 4 lower
gastrointestinal or genitourinary toxicity (RTOG acute toxicity
criteria), or perineal skin toxicity or any other grade 4 toxicity
(RTOG acute toxicity criteria or NCIC Toxicity Criteria). A delay of
48 weeks before surgery for toxicity reasons after completing
concurrent therapy was also considered a DLT. If the cohort at the
starting dose level experienced toxicity defined as DLT, the dose
was reduced to the preceding dose level, being two-thirds of the
initial level until the treatment was considered to be tolerable.
Trial treatments
Pelvic radiotherapy was given with a megavoltage machine
(6–18MeV) using a three- or four-field technique. The patient
was treated in the prone position. A belly board and other methods
were used to minimise treatment-related toxicity. Computerised
dosimetry was routinely performed. The total radiation dose was
50.4Gy in 1.8Gy per fraction per day, 5 days per week. The first
45Gy was given to the pelvic field and 5.4Gy in three fractions
were given to the reduced field. The total duration of treatment was
5 weeks and 3 days. The planning target volume for the pelvic field
was: upper border at the L5/S1 junction, inferior border 3cm
below the primary tumour or at the inferior aspect of the obturator
foramina, whichever was the most inferior, lateral border 1.5cm
lateral to the widest bony margin of the true pelvic side wall,
anterior border 2cm from the anterior boundary of the
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lmesorectum and posterior border a minimum of 1cm behind the
anterior bony sacral margin. For the reduced field, a 2cm margin
was given to the site of gross disease. All radiation fields were
treated daily, Monday to Friday. Verification port films were
performed weekly.
Radiotherapy was temporarily interrupted at the investigator’s
discretion if there was grade 3 or 4 toxicity. The decision to
interrupt treatment was taken only after discussion with the
principal investigators. Radiotherapy was to recommence once
toxicity had decreased to grade 2 or lower. If recovery of toxicity to
grade 2 or less had not occurred after a 2-week delay, the treatment
was ceased.
The planned escalating dose levels of capecitabine were 850,
1000, 1250, 1650, 1800, 2000 and 2500mgm
 2day
 1. Three
patients were planned for each cohort. The cohort was expanded
according to the previously described schedule. Capecitabine was
given twice daily, Monday to Friday. The first daily dose of
capecitabine was administered approximately 2h730min before
radiotherapy, at the same time every day, throughout the entire
period of radiation. Capecitabine and radiotherapy treatment were
commenced on the same day and were ceased together at
completion of the preoperative therapy. The whole duration was
5 weeks and 3 working days (28 days). The total daily dose was
divided into two approximately equal lots and administered
separately approximately 12h apart and within 30min after the
ingestion of food. Surgery (using total mesorectal excision) was
performed after a rest period of 4–7 weeks from completion of the
preoperative chemoradiation. In patients receiving low anterior
resections, defunctioning ileostomy or colostomy was recom-
mended.
Dose modifications for toxicity
Treatment was continued without modification for grade 1
toxicity. If a patient experienced any grade 2 toxicity and the
toxicity was considered to be mainly due to capecitabine
treatment, drug administration was withheld until the grade 2
toxicity resolved to grade 0–1 before being restarted at the same
dose with prophylactic treatment (for nausea, diarrhoea, hand–
foot syndrome) where necessary and possible. If grade 2 toxicity
recurred, capecitabine treatment was withheld until the toxicity
resolved to grade 0–1 and the capecitabine treatment was restarted
at the preceding dose level. In cases in which toxicity recurred at
the starting dose level, capecitabine treatment was discontinued
for the rest of the course of radiotherapy. In each of these
circumstances, radiotherapy was not affected unless the described
toxicity worsened after discontinuing capecitabine. If a patient
experienced any grade 2 toxicity, which was mainly cutaneous,
radiotherapy and capecitabine treatment were continued. If a
patient experienced any grade 3 or 4 toxicity, with the exception of
alopecia, which was considered mainly due to capecitabine
treatment, both capecitabine and radiotherapy treatment were
discontinued. Radiotherapy was recommenced without capecita-
bine for the remaining course of treatment once the toxicity had
improved to grade 0–2. Capecitabine treatment was discontinued
for any grade 3 or 4 haematological toxicity.
Monitoring for safety
Assessments before treatment included demographic data, medical
history, physical examination, haematology, renal and liver
function tests, CEA, pregnancy test (if appropriate), and chest X-
ray, ECG, abdominal and pelvic CT, endorectal ultrasound and
PET scan. Routine assessments, performed prior to the start of
treatment, weekly thereafter for 6 weeks and every second week up
to 6 weeks after the last radiotherapy administration included vital
signs, physical measurements, haematology, blood chemistry,
urinalysis and monitoring of adverse events.
Statistical considerations
This trial aimed to identify the MTD of intermittent twice daily
oral capecitabine in combination with concurrent, standard
radiotherapy. An escalating dose design was employed, in which
a maximum of 12 patients could be entered at each dose level. The
MTD was defined to be the first dose that caused a DLT (grade 3/4
toxicity – see prior section) in one-third or more of the patients
treated. These prespecified rules were based on clinical and ethical
considerations, rather than on statistical methods. The analyses of
the primary and secondary efficacy variables comprised simple
descriptive statistics, summary tables, plots and patient listings.
The descriptive statistics included the mean, standard deviation,
standard error, minimum and maximum for continuous variables.
The median was used as the measure of central tendency for
any time-to-failure end points. Counts and percentages were
provided for discrete variables. The data were analysed using SAS
version 8.2.
RESULTS
Patient characteristics
In all, 28 patients were enrolled in the trial. The mean age was 62.3
years, with a range of 33–80 years. Of these, 27 of the patients were
Caucasians and one was Asian. Five patients were female and 23
were male. The WHO performance status of patients at the time of
screening was mainly level 1 (54%) and level 2 (43%). The median
distance of the lower border of the tumour to the anal verge was
6cm (range: 1–11cm). Rectal ultrasound examinations were
performed in 93% of patients. A total of 26 patients (93%) had
T3 disease and two patients had resectable T4 disease. The clinical
stages of disease before treatment are listed in Table 1.
Dose level
The dose levels of the patients accrued into this trial were:
850mgm
 2day
 1 (n¼3), 1000mgm
 2day
 1 (n¼6), 1250mgm
 2day
 1
(n¼3), 1650mgm
 2day
 1 (n¼3), 1800mgm
 2day
 1 (n¼8) and
2000mgm
 2day
 1 (n¼5).
Adverse events
Four DLTs occurred in three patients – one of six patients at a dose
of 1000mgm
 2day
 1 and two of five patients at a dose of
2000mgm
 2day
 1. Dose escalation was stopped at
2000mgm
 2day
 1 – the protocol-defined MTD of capecitabine
in this study. After reaching MTD at 2000mgm
 2day
 1, five
additional patients were treated at 1800mgm
 2day
 1 giving the
1800mgm
 2day
 1 cohort a total of eight patients. The patient
with a DLT at the dose level of 1000mgm
 2day
 1 developed grade
3 urological toxicity at day 12 of treatment, which resolved slowly
after discontinuation of all treatment. One patient at dose level
2000mgm
 2day
 1 developed a DLT with grade 3 perineal skin
toxicity requiring opioid analgesics at day 14 of treatment. A
second patient at this dose level developed two DLTs – grade 3
diarrhoea and grade 3 dehydration on day 22.
Table 1 Pretreatment clinical stage
Clinical stage
T3N0 13 (46)
T3N1 13 (46)
T4N0 1 (4)
T4N1 1 (4)
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the preoperative therapy. The most common adverse events were
gastrointestinal disorders with 15 patients (54%) reporting at least
one such event, skin and subcutaneous tissue disorders in nine
patients (32%) reporting at least one such event, general disorders
such as fatigue or pain in eight patients (23%) and renal and
urinary disorders in six patients (21%). Hand–foot syndrome
occurred in 11% of patients: grade 1, 3.6% and grade 2, 7.1%.
There was no grade 2 or 3 neutropenia or thrombocytopenia
encountered. Table 2 shows the acute toxicity according to dose
levels.
Surgical morbidity
Surgical resection of the rectal cancer was performed after
preoperative chemoradiation in 27 patients. One patient refused
to have surgery after achieving a clinical complete response.
Sphincter sparing surgery was performed in 44% (12 patients).
Abdominoperineal resection was performed in 52% (14 patients).
Proctocolectomy was performed in one patient. There was one
postoperative death. The patient developed an acute myocardial
infarct and died 4 days after operation. The postoperative
complications are listed in Table 3.
Antitumour activity
Out of a total of 27 patients, 15 had a lower T stage (by at least one
stage) in the resected specimen compared with pretreatment
clinical stage after preoperative chemoradiation. Five patients
(19%) achieved a pathologic complete response (no evidence of
disease in the resected specimen). Table 4 shows the correlation
between the pretreatment clinical stage and the postsurgery
pathologic stage.
Table 2 Acute toxicities (worst grade)
Toxicities Grade 850mgm
 2day
 1 1000mgm
 2day
 1 1250mgm
 2day
 1 1650mgm
 2day
 1 1800mgm
 2day
 1 2000mgm
 2day
 1
Haemoglobin
0 1 42254
1 0 00121
2 2 21010
Neutrophils
0 3 63375
1 0 00010
Platelets
0 3 52265
1 0 11120
Genitourinary
0 1 23122
1 2 20162
2 0 10101
3 0 10000
Lower GI
0 0 20120
1 2 13251
2 1 30013
3 0 00001
Skin
0 0 00211
1 1 13162
2 2 50011
3 0 00001
Hand-foot syndrome
0 3 53365
1 0 00010
2 0 10010
Table 3 Postoperative complications
Complications Number of events
Wound complications 5
Infection 5
Urinary tract complications 3
Nausea and vomiting 3
Abdominal distension and ileus 2
Anaemia 2
Thrombosis 1
Haemorrhage 1
Rectal bleeding 1
Anal ulcer 1
Abdominal pain 1
Cardiogenic shock 1
Cerebral infarction 1
Leukopenia 1
Note: Surgical procedures n¼27, as one patient refused surgery. Each patient may
have more than one event.
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In advanced colorectal cancer, capecitabine is generally adminis-
tered in an intermittent schedule of 1250mgm
 2 twice daily
(2500mgm
 2day
 1) for 2 weeks followed by a 1-week treatment
break. However, combined with radiotherapy, a continuous
regimen seemed to be a hypothetically more attractive schedule,
mimicking the postoperative adjuvant setting, in which the
optimal approach to the treatment of resected T3–4/N0–2 rectal
cancer includes radiotherapy combined with concurrent, contin-
uous infusion 5FU (O’Connell et al, 1994). Furthermore,
in nonrandomised trials of preoperative radiotherapy combined
with continuous infusion 5FU, a pathologic complete response
rate of 16–29%, low toxicity profile and no obvious increase
in surgical morbidity have been reported (Rich et al, 1995;
Ngan et al, 2001).
Infusional 5FU requires an ambulatory infusion device and
continuous intravenous access. It carries risks of infection, venous
thrombosis, intravenous line blockage and is inconvenient to
patients. Capecitabine, an effective oral agent commonly used in
MCRC, avoids all of these problems. In this phase I trial, the
schedule of capecitabine was designed to simulate infusional 5FU
to maximise radiosensitisation and cytotoxicity. Conventional,
fractionated radiotherapy was given 5 days per week (Monday to
Friday) and capecitabine was only given on the days of radio-
therapy. The advantage of a ‘drug-free’ period of 2 days per week
not only was thought to be more convenient but may have
increased the dose intensity and hence radiosensitisation of
chemotherapy.
In this trial, dose escalation of capecitabine was discontinued at
the MTD of 2000mgm
 2day
 1 with two of five patients having
developed a DLT. The three DLTs that occurred in these two
patients were perineal cutaneous reactions, diarrhoea and
dehydration. Overall, hand–foot syndrome was uncommon with
grade 1 in one patient and grade 2 in two patients out of the total of
28 patients. The haematological toxicity of this regimen was also
low with no grade 3 toxicity. Combined with concurrent
preoperative conventionally fractionated radiation, a dose of
capecitabine of 1800mgm
 2day
 1 was recommended for further
study for locally advanced resectable rectal cancer. None of the
eight patients at this dose level (1800mgm
 2day
 1) experienced a
DLT.
In contrast, in a German trial in which the majority of patients
(all with rectal cancer) were treated postoperatively and
capecitabine was given 7 days a week throughout the course of
pelvic radiotherapy (Dunst et al, 2002), two of the six patients
treated with capecitabine at a dose of 2000mgm
 2day
 1
experienced grade 3 hand–foot syndrome. Dose escalation was
stopped at 2000 and 1650mgm
 2day
 1 was the recommended
dose for further evaluation. In a similar phase I trial from Greece
(Souglakos et al, 2003), in which capecitabine was given
continuously throughout the period of radiotherapy (in this study
given postoperatively to all patients), three of the six patients
developed a DLT, including one with grade 3 hand–foot
syndrome and dose escalation was ceased at a capecitabine dose
of 1700mgm
 2day
 1. In this trial, grade 1 hand–foot syndrome
was noted in three out of 10 patients and grade 2 in three out of
10 patients. A Korean group has also reported their experience of
oral capecitabine and concurrent radiation for rectal cancer
treating 45 patients with clinical T3/T4 or node-positive rectal
cancer preoperatively to 50.4Gy (Kim et al, 2002). The
chemotherapy schedule used in this study consisted of two cycles
of the intermittent schedule (14 days of capecitabine
1650mgm
 2day
 1 and leucovorin 20mgm
 2day
 1 followed by
a 7-day rest). Grade 3 hand–foot syndrome occurred in 7% of
patients (grade 1, 31%, grade 2, 9% of patients). The other grade 3
toxicities included fatigue in 4%, diarrhoea in 4% and radiation
dermatitis in 2% of patients.
Our study only included patients with T3 or resectable T4 rectal
cancer. The clinical stage of the tumour was confirmed in the
majority of cases (93%) with endorectal ultrasound. All except one
patient underwent resection after preoperative therapy, providing
a better opportunity than in previous studies to evaluate the
antitumour activity of capecitabine combined with concurrent,
preoperative radiotherapy. Pathologic complete response was
noted in five of the 27 evaluable patients (19%). A total
of 15 patients (56%) showed downstaging of the pretreat-
ment clinical T stage by at least one stage compared to the
pathologic T stage. This result was similar to a previous
Australasian phase II trial with continuous infusion 5FU using
similar radiation protocols and selection criteria (Ngan et al,
2001). In that trial, the pathologic complete response rate was 16%
and downstaging of the pretreatment clinical T stage by at least
one stage compared to the pathologic T stage was seen in 54% of
patients.
In the German phase I trial, only 10 patients underwent
preoperative chemoradiation, and of these, pathologic complete
response was observed in one patient. In the phase I trial from
Greece, antitumour activity could not be assessed because all
patients were treated postoperatively. In the Korean study, 38 of
the 45 patients received definitive surgery. Two patients only had a
transanal excision and five patients refused surgery after complet-
ing the preoperative chemoradiation. The pathologic complete
response rate for the group of patients who underwent definitive
surgery was 31% (12 of 38). However, endorectal ultrasound was
only performed in 18% of patients so that the extent of
downstaging could not be accurately assessed.
Our trial also provided an opportunity for a formal assessment
of the surgical morbidity from preoperative radiotherapy and
concurrent capecitabine. The surgical morbidity was comparable
with the Australasian preoperative radiotherapy trial with
infusional 5FU. Surgical morbidity data were not presented for
the 10 patients treated preoperatively in the German trial. In the
Korean study, the postoperative complications listed were
neurogenic bladder (one patient), intestinal obstruction (two
patients including one patient who required surgery), anastomotic
leakage requiring surgery (one patient) and rectovaginal fistula
requiring surgery (one patient). Postoperative complications of
our trial are summarised in Table 3.
CONCLUSION
We conclude that the MTD of capecitabine was reached at a dose
level of 2000mgm
 2day
 1, given as 1000mgm
 2 twice daily, from
Monday to Friday throughout the course of preoperative pelvic
irradiation of 50.4Gy. For patients with resectable rectal cancer
receiving concurrent, full dose radiotherapy, the recommended
dose of capecitabine for further study is 1800mgm
 2day
 1 when
given in this schedule.
Table 4 Comparison of pretreatment clinical T stage and pathological
T stage after preoperative chemoradiation
Pathological T stage
Clinical T stage 0 1 2 3 4 X Total
3 50812 0 1
a 26
4 010 100 2
Total 5 1 8 13 0 1 28
Note: Bold numerals represent downstaging by at least one stage.
aPatient refused
surgery.
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